Laurel Wealth Advisors (North Carolina)’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.63M | Sell |
30,317
-185
| -0.6% | -$39.8K | 0.74% | 29 |
|
|
2026
Q1 | $6.15M | Buy |
30,502
+105
| +0.3% | +$23.3K | 0.61% | 33 |
|
|
2025
Q4 | $6.95M | Sell |
30,397
-448
| -1% | -$102K | 0.92% | 29 |
|
|
2025
Q3 | $7.14M | Buy |
30,845
+104
| +0.3% | +$21.2K | 1% | 25 |
|
|
2025
Q2 | $5.71M | Sell |
30,741
-128
| -0.4% | -$23.8K | 0.85% | 33 |
|
|
2025
Q1 | $6.47M | Sell |
30,869
-524
| -2% | -$102K | 1.01% | 26 |
|
|
2024
Q4 | $5.58M | Sell |
31,393
-344
| -1% | -$63.2K | 0.87% | 30 |
|
|
2024
Q3 | $6.27M | Sell |
31,737
-450
| -1% | -$84K | 1% | 26 |
|
|
2024
Q2 | $5.52M | Sell |
32,187
-959
| -3% | -$159K | 0.96% | 26 |
|
|
2024
Q1 | $6.04M | Sell |
33,146
-134
| -0.4% | -$23.1K | 1.03% | 26 |
|
|
2023
Q4 | $5.16M | Sell |
33,280
-64
| -0.2% | -$9.33K | 0.98% | 29 |
|
|
2023
Q3 | $4.97M | Sell |
33,344
-2,104
| -6% | -$309K | 1.05% | 28 |
|
|
2023
Q2 | $4.78M | Sell |
35,448
-1,185
| -3% | -$174K | 0.96% | 30 |
|
|
2023
Q1 | $5.84M | Buy |
36,633
+653
| +2% | +$99.8K | 1.23% | 23 |
|
|
2022
Q4 | $5.81M | Buy |
35,980
+2,788
| +8% | +$427K | 1.32% | 21 |
|
|
2022
Q3 | $4.46M | Buy |
33,192
+2,444
| +8% | +$351K | 1.11% | 25 |
|
|
2022
Q2 | $4.71M | Buy |
30,748
+765
| +3% | +$117K | 1.14% | 27 |
|
|
2022
Q1 | $4.86M | Sell |
29,983
-366
| -1% | -$53.2K | 1.02% | 27 |
|
|
2021
Q4 | $4.11M | Buy |
30,349
+1,245
| +4% | +$147K | 0.84% | 35 |
|
|
2021
Q3 | $3.14M | Sell |
29,104
-1,318
| -4% | -$151K | 0.69% | 47 |
|
|
2021
Q2 | $3.43M | Buy |
30,422
+2,266
| +8% | +$255K | 0.74% | 41 |
|
|
2021
Q1 | $3.05M | Buy |
28,156
+2,670
| +10% | +$286K | 0.74% | 45 |
|
|
2020
Q4 | $2.73M | Buy |
25,486
+3,545
| +16% | +$341K | 0.71% | 45 |
|
|
2020
Q3 | $1.92M | Buy |
21,941
+4,312
| +24% | +$406K | 0.57% | 53 |
|
|
2020
Q2 | $1.73M | Buy |
17,629
+6,834
| +63% | +$602K | 0.57% | 56 |
|
|
2020
Q1 | $822K | Buy |
10,795
+1,175
| +12% | +$100K | 0.31% | 73 |
|
|
2019
Q4 | $852K | Sell |
9,620
-195
| -2% | -$16.2K | 0.27% | 74 |
|
|
2019
Q3 | $743K | Sell |
9,815
-660
| -6% | -$45.2K | 0.25% | 79 |
|
|
2019
Q2 | $762K | Sell |
10,475
-62
| -0.6% | -$4.87K | 0.27% | 77 |
|
|
2019
Q1 | $849K | Sell |
10,537
-360
| -3% | -$29.5K | 0.31% | 72 |
|
|
2018
Q4 | $1M | Buy |
+10,897
| New | +$958K | 0.4% | 66 |
|
Other funds holding ABBV
Laurel Wealth Advisors (North Carolina)'s ABBV Position: Q2 2026 in Review
Laurel Wealth Advisors (North Carolina) reduced its AbbVie (ABBV) stake by 0.61% in Q2 2026, selling an estimated $39.8K and leaving 30,317 shares worth $7.63M. The position accounts for 0.74% of the portfolio, ranked #29.
Laurel Wealth Advisors (North Carolina) first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Laurel Wealth Advisors (North Carolina) held 30,317 shares of AbbVie worth $7.63M as of Q2 2026.
- Laurel Wealth Advisors (North Carolina) sold 185 AbbVie shares in Q2 2026, an estimated $39.8K.
- AbbVie made up 0.74% of Laurel Wealth Advisors (North Carolina)'s portfolio in Q2 2026, its #29 holding.
- Laurel Wealth Advisors (North Carolina) first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q2 2026, filed 17 Jul 2026.